{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:14:27Z","timestamp":1792700067736,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T00:00:00Z","timestamp":1548460800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Probiotics &amp; Antimicro. Prot."],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s12602-019-9517-0","type":"journal-article","created":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T19:02:27Z","timestamp":1548529347000},"page":"152-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effect of Probiotic Use on Adverse Events in Adult Patients with Inflammatory Bowel Disease: a Retrospective Cohort Study"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7305-3531","authenticated-orcid":false,"given":"Maria Pina","family":"Dore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio Pio","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Mario","family":"Scanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Vidili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Padedda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Mario","family":"Pes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,26]]},"reference":[{"key":"9517_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMra020831","volume":"347","author":"DK Podolsky","year":"2002","unstructured":"Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417\u2013429. \nhttps:\/\/doi.org\/10.1056\/NEJMra020831","journal-title":"N Engl J Med"},{"key":"9517_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.cgh.2016.10.039","volume":"15","author":"R Shivashankar","year":"2017","unstructured":"Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr (2017) Incidence and prevalence of Crohn\u2019s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol 15:857\u2013863. \nhttps:\/\/doi.org\/10.1016\/j.cgh.2016.10.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9517_CR3","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2018","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG (2018) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390:2769\u20132778. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(17)32448-0","journal-title":"Lancet"},{"key":"9517_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2036.2006.03134.x","volume":"25","author":"S Vermeire","year":"2007","unstructured":"Vermeire S, van Assche G, Rutgeerts P (2007) Altering the natural history of Crohn\u2019s disease \u2013 evidence for and against current therapies. Aliment Pharmacol Ther 25:3\u201312. \nhttps:\/\/doi.org\/10.1111\/j.1365-2036.2006.03134.x","journal-title":"Aliment Pharmacol Ther"},{"key":"9517_CR5","doi-asserted-by":"publisher","unstructured":"Beaugerie L, Kirchgesner J (2018) Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. \nhttps:\/\/doi.org\/10.1016\/j.cgh.2018.07.013","DOI":"10.1016\/j.cgh.2018.07.013"},{"issue":"Suppl 1","key":"9517_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jgh.12751","volume":"30","author":"C Fiocchi","year":"2015","unstructured":"Fiocchi C (2015) Inflammatory bowel disease pathogenesis: where are we? J Gastroenterol Hepatol 30(Suppl 1):12\u201318. \nhttps:\/\/doi.org\/10.1111\/jgh.12751","journal-title":"J Gastroenterol Hepatol"},{"key":"9517_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cell.2007.08.017","volume":"131","author":"WS Garrett","year":"2007","unstructured":"Garrett WS, Lord GM, Punit S, Punit S, Lugo-Villarino G, Mazmanian SK et al (2007) Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131:33\u201345. \nhttps:\/\/doi.org\/10.1016\/j.cell.2007.08.017","journal-title":"Cell"},{"key":"9517_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.cell.2011.04.022","volume":"145","author":"E Elinav","year":"2011","unstructured":"Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, Peaper DR, Bertin J, Eisenbarth SC, Gordon JI, Flavell RA (2011) NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145:745\u2013757. \nhttps:\/\/doi.org\/10.1016\/j.cell.2011.04.022","journal-title":"Cell"},{"key":"9517_CR9","doi-asserted-by":"publisher","unstructured":"Shukla PK, Meena AS, Manda B, Gomes-Solecki M, Dietrich P, Dragatsis I, Rao R (2018) Lactobacillus plantarum prevents and mitigates alcohol-induced disruption of colonic epithelial tight junctions, endotoxemia, and liver damage by an EGF receptor-dependent mechanism. FASEB J. \nhttps:\/\/doi.org\/10.1096\/fj.201800351R","DOI":"10.1096\/fj.201800351R"},{"key":"9517_CR10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3389\/fmicb.2017.00486","volume":"8","author":"TP Singh","year":"2017","unstructured":"Singh TP, Kaur G, Kapila S, Malik RK (2017) Antagonistic activity of Lactobacillus reuteri strains on the adhesion characteristics of selected pathogens. Front Microbiol 8:486. \nhttps:\/\/doi.org\/10.3389\/fmicb.2017.00486","journal-title":"Front Microbiol"},{"key":"9517_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1053\/gast.2001.27224","volume":"121","author":"K Madsen","year":"2001","unstructured":"Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, de Simone C (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121:580\u2013591. \nhttps:\/\/doi.org\/10.1053\/gast.2001.27224","journal-title":"Gastroenterology"},{"key":"9517_CR12","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1002\/1521-3773(20000804)39:15<2766::AID-ANIE2766>3.0.CO;2-G","volume":"39","author":"A H\u00f6ltzel","year":"2000","unstructured":"H\u00f6ltzel A, G\u04d3nzle MG, Nicholson GJ (2000) The first low molecular weight antibiotic from lactic acid bacteria: reutericyclin, a new tetramic acid. Angew Chem Int Ed Engl 39:2766\u20132768. \nhttps:\/\/doi.org\/10.1002\/1521-3773(20000804)39:15<2766::AID-ANIE2766>3.0.CO;2-G","journal-title":"Angew Chem Int Ed Engl"},{"key":"9517_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1574-695X.2002.tb00541.x","volume":"32","author":"T Mukai","year":"2002","unstructured":"Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H (2002) Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 32:105\u2013110. \nhttps:\/\/doi.org\/10.1111\/j.1574-695X.2002.tb00541.x","journal-title":"FEMS Immunol Med Microbiol"},{"key":"9517_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12602-017-9322-6","volume":"10","author":"G Fata La","year":"2018","unstructured":"La Fata G, Weber P, Mohajeri MH (2018) Probiotics and the gut immune system: indirect regulation. Probiotics Antimicrob Proteins 10:11\u201321. \nhttps:\/\/doi.org\/10.1007\/s12602-017-9322-6","journal-title":"Probiotics Antimicrob Proteins"},{"key":"9517_CR15","doi-asserted-by":"publisher","first-page":"12553","DOI":"10.1038\/s41598-018-31006-3","volume":"8","author":"K Elbanna","year":"2018","unstructured":"Elbanna K, El Hadad S, Assaeedi A (2018) In vitro and in vivo evidences for innate immune stimulators lactic acid bacterial starters isolated from fermented camel dairy products. Sci Rep 8:12553. \nhttps:\/\/doi.org\/10.1038\/s41598-018-31006-3","journal-title":"Sci Rep"},{"key":"9517_CR16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/gut.2003.037747","volume":"53","author":"W Kruis","year":"2004","unstructured":"Kruis W, Fric P, Pokrotnieks J, Luk\u00e1s M, Fixa B, Kasc\u00e1k M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617\u20131623. \nhttps:\/\/doi.org\/10.1136\/gut.2003.037747","journal-title":"Gut"},{"key":"9517_CR17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1046\/j.1365-2036.1997.00225.x","volume":"11","author":"W Kruis","year":"1997","unstructured":"Kruis W, Sch\u00fctz E, Fric P, Fixa B, Judmaier G, Stolte M (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11:853\u2013858. \nhttps:\/\/doi.org\/10.1046\/j.1365-2036.1997.00225.x","journal-title":"Aliment Pharmacol Ther"},{"key":"9517_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1472-6882-10-13","volume":"10","author":"H Matthes","year":"2010","unstructured":"Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J (2010) Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 10:13. \nhttps:\/\/doi.org\/10.1186\/1472-6882-10-13","journal-title":"BMC Complement Altern Med"},{"key":"9517_CR19","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.crohns.2014.06.001","volume":"8","author":"AM Petersen","year":"2014","unstructured":"Petersen AM, Mirsepasi H, Halkj\u00e6r SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA (2014) Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis 8:1498\u20131505. \nhttps:\/\/doi.org\/10.1016\/j.crohns.2014.06.001","journal-title":"J Crohns Colitis"},{"key":"9517_CR20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1365-2036.2004.02268.x","volume":"20","author":"K Kato","year":"2004","unstructured":"Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y (2004) Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 20:1133\u20131141. \nhttps:\/\/doi.org\/10.1111\/j.1365-2036.2004.02268.x","journal-title":"Aliment Pharmacol Ther"},{"key":"9517_CR21","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.cgh.2009.07.016","volume":"11","author":"A Sood","year":"2009","unstructured":"Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK (2009) The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 11:1202\u20131209. \nhttps:\/\/doi.org\/10.1016\/j.cgh.2009.07.016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9517_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/den.12553","volume":"28","author":"H Tamaki","year":"2016","unstructured":"Tamaki H, Nakase H, Inoue S, Kawanami C, Itani T, Ohana M, Kusaka T, Uose S, Hisatsune H, Tojo M, Noda T, Arasawa S, Izuta M, Kubo A, Ogawa C, Matsunaka T, Shibatouge M (2016) Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc 28:67\u201374. \nhttps:\/\/doi.org\/10.1111\/den.12553","journal-title":"Dig Endosc"},{"key":"9517_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/apt.14203","volume":"46","author":"Y Derwa","year":"2017","unstructured":"Derwa Y, Gracie DJ, Hamlin PJ, Ford AC (2017) Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 46:389\u2013400. \nhttps:\/\/doi.org\/10.1111\/apt.14203","journal-title":"Aliment Pharmacol Ther"},{"key":"9517_CR24","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41395-018-0138-0","volume":"113","author":"RL Koretz","year":"2018","unstructured":"Koretz RL (2018) Probiotics in gastroenterology: how pro is the evidence in adults? Am J Gastroenterol 113:1125\u20131136. \nhttps:\/\/doi.org\/10.1038\/s41395-018-0138-0","journal-title":"Am J Gastroenterol"},{"key":"9517_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2018.1527998","volume":"19","author":"R Satta","year":"2018","unstructured":"Satta R, Pes GM, Rocchi C, Pes MC, Dore MP (2018) Is probiotic use beneficial for skin lesions in patients with inflammatory bowel disease? J Dermatol Treat 19:1\u20135. \nhttps:\/\/doi.org\/10.1080\/09546634.2018.1527998","journal-title":"J Dermatol Treat"},{"key":"9517_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/1269547","volume":"34","author":"D Lambert","year":"1992","unstructured":"Lambert D (1992) Zero-inflated Poisson regression, with an application to defects in manufacturing. Technometrics 34:1\u201314","journal-title":"Technometrics"},{"key":"9517_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An introduction to the bootstrap","author":"B Efron","year":"1993","unstructured":"Efron B, Tibshirani R (1993) An introduction to the bootstrap. Chapman & Hall, New York"},{"key":"9517_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-230X-4-5","volume":"4","author":"M Schultz","year":"2004","unstructured":"Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC (2004) Lactobacillus GG in inducing and maintaining remission of Crohn\u2019s disease. BMC Gastroenterol 4:5. \nhttps:\/\/doi.org\/10.1186\/1471-230X-4-5","journal-title":"BMC Gastroenterol"},{"key":"9517_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/00004836-199712000-00021","volume":"25","author":"HA Malchow","year":"1997","unstructured":"Malchow HA (1997) Crohn\u2019s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn\u2019s disease? J Clin Gastroenterol 25:653\u2013658","journal-title":"J Clin Gastroenterol"},{"key":"9517_CR30","doi-asserted-by":"publisher","unstructured":"Ganji-Arjenaki M, Rafieian-Kopaei M (2018) Probiotics are a good choice in remission of inflammatory bowel diseases: a meta-analysis and systematic review. J Cell Physiol 233:2091\u20132103. \nhttps:\/\/doi.org\/10.1002\/jcp.25911","DOI":"10.1002\/jcp.25911"},{"key":"9517_CR31","doi-asserted-by":"publisher","first-page":"S-517","DOI":"10.1016\/S0016-5085(10)62390-6","volume":"138","author":"RP Willert","year":"2010","unstructured":"Willert RP, Peddi KK, Ombiga J, Bampton PA, Lawrance IC (2010) Randomised, double-blinded, placebo-controlled study of VSL#3 versus placebo in the maintenance of remission in Crohns disease. Gastroenterology 138:S-517. \nhttps:\/\/doi.org\/10.1016\/S0016-5085(10)62390-6","journal-title":"Gastroenterology"},{"key":"9517_CR32","doi-asserted-by":"publisher","unstructured":"Bourreille A, Cadiot G, Le Dreau G, Laharie D, Beaugerie L, Dupas JL et al (2013) Saccharomyces boulardii does not prevent relapse of Crohn\u2019s disease. Clin Gastroenterol Hepatol 11:982\u2013987. \nhttps:\/\/doi.org\/10.1016\/j.cgh.2013.02.021","DOI":"10.1016\/j.cgh.2013.02.021"},{"key":"9517_CR33","doi-asserted-by":"publisher","unstructured":"Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000) Saccharomyces boulardii in maintenance treatment of Crohn\u2019s disease. Dig Dis Sci 45:1462\u20131464. \nhttps:\/\/doi.org\/10.1023\/A:1005588911207","DOI":"10.1023\/A:1005588911207"},{"key":"9517_CR34","doi-asserted-by":"publisher","unstructured":"Katz M (2012) Study design and statistical analysis: a practical guide for clinicians, 2006. In: Wanburg C (ed) The Oxford handbook of organizational socialization.\u00a0\nhttps:\/\/doi.org\/10.1017\/CBO9780511616761","DOI":"10.1017\/CBO9780511616761"},{"key":"9517_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/apt.13511","volume":"43","author":"N To","year":"2016","unstructured":"To N, Gracie DJ, Ford AC (2016) Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn\u2019s disease. Aliment Pharmacol Ther 43:549\u2013561. \nhttps:\/\/doi.org\/10.1111\/apt.13511","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Probiotics and Antimicrobial Proteins"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-019-9517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12602-019-9517-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-019-9517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T22:24:31Z","timestamp":1584224671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12602-019-9517-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["9517"],"URL":"https:\/\/doi.org\/10.1007\/s12602-019-9517-0","relation":{},"ISSN":["1867-1306","1867-1314"],"issn-type":[{"value":"1867-1306","type":"print"},{"value":"1867-1314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,26]]},"assertion":[{"value":"26 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from each patient enrolled. The study was approved by the Local Ethics Committee, <i>Comitato di Bioetica, Azienda Ospedaliero Universitaria di Sassari<\/i>, Italy (Prot. No. 2476\/CE.), and the 1975 Declaration of Helsinki guidelines were followed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}